Our Tests Clinical Science Resources About Us For Patients For Investors Contact Us Answer endocrine treatment planning questions with assurance One Platform. Multiple answers. In a single genomic test – and as part of the most comprehensive platform available to support treatment planning for early-stage breast cancer – MammaPrint empowers clinicians with actionable information to answer important benefit questions regarding chemotherapy, standard of care endocrine therapy, and extended endocrine therapy. Want more information? I AM* Physician Patient Nurse Navigator Registered Nurse Other Nurse Other Staff Researcher Investor Other Patient Advocate B2B Media  FIRST NAME* LAST NAME* EMAIL* State / Province / Region Country Afghanistan Albania Algeria American Samoa Andorra Angola Anguilla Antarctica Antigua and Barbuda Argentina Armenia Aruba Australia Austria Azerbaijan Bahamas Bahrain Bangladesh Barbados Belarus Belgium Belize Benin Bermuda Bhutan Bolivia Bonaire, Sint Eustatius and Saba Bosnia and Herzegovina Botswana Bouvet Island Brazil British Indian Ocean Territory Brunei Darussalam Bulgaria Burkina Faso Burundi Cambodia Cameroon Canada Cape Verde Cayman Islands Central African Republic Chad Chile China Christmas Island Cocos Islands Colombia Comoros Congo, Democratic Republic of the Congo, Republic of the Cook Islands Costa Rica Croatia Cuba Curaçao Cyprus Czech Republic Côte d'Ivoire Denmark Djibouti Dominica Dominican Republic Ecuador Egypt El Salvador Equatorial Guinea Eritrea Estonia Eswatini (Swaziland) Ethiopia Falkland Islands Faroe Islands Fiji Finland France French Guiana French Polynesia French Southern Territories Gabon Gambia Georgia Germany Ghana Gibraltar Greece Greenland Grenada Guadeloupe Guam Guatemala Guernsey Guinea Guinea-Bissau Guyana Haiti Heard and McDonald Islands Holy See Honduras Hong Kong Hungary Iceland India Indonesia Iran Iraq Ireland Isle of Man Israel Italy Jamaica Japan Jersey Jordan Kazakhstan Kenya Kiribati Kuwait Kyrgyzstan Lao People's Democratic Republic Latvia Lebanon Lesotho Liberia Libya Liechtenstein Lithuania Luxembourg Macau Macedonia Madagascar Malawi Malaysia Maldives Mali Malta Marshall Islands Martinique Mauritania Mauritius Mayotte Mexico Micronesia Moldova Monaco Mongolia Montenegro Montserrat Morocco Mozambique Myanmar Namibia Nauru Nepal Netherlands New Caledonia New Zealand Nicaragua Niger Nigeria Niue Norfolk Island North Korea Northern Mariana Islands Norway Oman Pakistan Palau Palestine, State of Panama Papua New Guinea Paraguay Peru Philippines Pitcairn Poland Portugal Puerto Rico Qatar Romania Russia Rwanda Réunion Saint Barthélemy Saint Helena Saint Kitts and Nevis Saint Lucia Saint Martin Saint Pierre and Miquelon Saint Vincent and the Grenadines Samoa San Marino Sao Tome and Principe Saudi Arabia Senegal Serbia Seychelles Sierra Leone Singapore Sint Maarten Slovakia Slovenia Solomon Islands Somalia South Africa South Georgia South Korea South Sudan Spain Sri Lanka Sudan Suriname Svalbard and Jan Mayen Islands Sweden Switzerland Syria Taiwan Tajikistan Tanzania Thailand Timor-Leste Togo Tokelau Tonga Trinidad and Tobago Tunisia Turkey Turkmenistan Turks and Caicos Islands Tuvalu US Minor Outlying Islands Uganda Ukraine United Arab Emirates United Kingdom United States Uruguay Uzbekistan Vanuatu Venezuela Vietnam Virgin Islands, British Virgin Islands, U.S. Wallis and Futuna Western Sahara Yemen Zambia Zimbabwe Åland Islands  WHAT ARE YOU INQUIRING ABOUT?* CAPTCHA For the US, Puerto Rico, Canada and South America Agendia Inc. USA 22 Morgan Irvine, CA 92618 (888) 321-2732 customercare@agendia.com For outside the Americas Agendia NV Radarweg 60 1043 NT Amsterdam The Netherlands customerservice@agendia.com +31 (0)20 462 1510 *MammaPrint Ultra Low Risk is a subset within the Low Risk category. Agendia’s laboratory is certified under the Clinical Laboratory Improvement Amendments (CLIA) as qualified to perform high-complexity clinical laboratory testing. MammaPrint and BluePrint have been CE-marked and are laboratory tests developed, validated and performed by Agendia. Quick Links Our Tests Resources Landmark Trials Order A Test For Patients Legal Privacy Policy Legal & Compliance Terms & Conditions Licenses & Accreditations Contact For the US, Puerto Rico, Canada and South America Agendia Inc. USA, 22 Morgan, Irvine, CA 92618 (888) 321-2732 customercare@agendia.com For outside the Americas Agendia NV, Radarweg 60, 1043 NT Amsterdam, The Netherlands +31 (0)20 462 1510 customerservice@agendia.com © 2021 Agendia. All rights reserved. MammaPrint and Blueprint are registered trademarks of Agendia, Inc. This website uses cookies to provide you with the best possible experience. By using this website, you agree to our terms and conditions and privacy policy. ACCEPT